| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 29,492 | 27,490 | 26,617 | 24,230 |
| Stock-based compensation | 10,191 | 9,768 | 9,691 | 18,470 |
| Deferred taxes | 2,515 | 2,356 | 18,800 | -6,919 |
| Loss (gain) on disposal of assets | NaN | -87 | -295 | 0 |
| Depreciation and amortization | 20,919 | 22,613 | 22,632 | 46,172 |
| Unrealized (gain) loss on investment in equity securities | 5,753 | 273 | 3,140 | -589 |
| Loss on extinguishment of debt | NaN | 0 | 0 | NaN |
| Non-cash operating lease expense | 453 | 555 | 358 | 846 |
| Amortization of inventory step up | NaN | 0 | 0 | NaN |
| Non-cash interest | 358 | 351 | 340 | 665 |
| Asset impairment charges | NaN | 0 | 767 | NaN |
| Contingent consideration fair value adjustment | -182 | -5,727 | -14,470 | -10,815 |
| Accounts receivable, net | -25,528 | 27,856 | 26,965 | 3,709 |
| Inventories | 437 | -3,732 | 8,160 | 1,533 |
| Prepaid expenses and other assets | -2,687 | 4,460 | 6,454 | -5,890 |
| Accounts payable | 5,358 | -7,235 | 13,766 | 8,625 |
| Accrued royalties | -14,655 | -2,750 | 15,217 | 13,404 |
| Income taxes | 14,087 | 472 | -12,548 | -3,455 |
| Accrued government rebates | -4,737 | 6,123 | 4,166 | 14,152 |
| Returned goods reserve | -6,451 | -502 | 1,322 | 9,409 |
| Accrued expenses, accrued compensation, and other | -20,998 | 5,623 | 1,821 | -5,218 |
| Net cash and cash equivalents provided by operating activities | 58,375 | 30,367 | 44,055 | 110,803 |
| Acquisition of alimera, net of cash acquired | NaN | NaN | 0 | NaN |
| Acquisition of alimera, net of cash acquired-Alimera | NaN | 0 | NaN | NaN |
| Proceeds from the sale of building | NaN | 0 | 0 | 0 |
| Acquisition of product rights, intangible assets, and other related assets | 5,250 | 159 | 60 | 20,267 |
| Acquisition of property and equipment, net | 6,074 | 1,244 | 6,103 | 6,488 |
| Net cash and cash equivalents used in investing activities | -11,324 | -1,403 | -6,163 | -26,755 |
| Proceeds from convertible notes | NaN | 0 | 0 | NaN |
| Proceeds from term loan | NaN | 0 | 0 | NaN |
| Purchase of capped call transaction | NaN | 0 | 0 | NaN |
| Proceeds from public offering | NaN | 0 | NaN | NaN |
| Payments on contingent consideration | NaN | 0 | 26 | 0 |
| Principal payments on borrowings | 4,063 | 10,156 | 0 | NaN |
| Debt issuance costs | NaN | 0 | 0 | NaN |
| Repayment on borrowings under credit agreement | NaN | -6,093 | 2,031 | 4,062 |
| Payment of accrued licensor payment | NaN | 0 | 0 | NaN |
| Series a convertible preferred stock dividends paid | 0 | 0 | 344 | 813 |
| Proceeds from stock option exercises and espp purchases | 2,202 | 38 | 9,790 | 3,776 |
| Treasury stock purchases for restricted stock vests | 19,755 | 611 | 1,044 | 10,554 |
| Net cash and cash equivalents used in financing activities | -21,616 | -4,636 | 6,345 | -11,653 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 156 | -1,353 | 576 | 544 |
| Net change in cash, cash equivalents, and restricted cash | 25,591 | 22,975 | 44,813 | 72,939 |
| Cash, cash equivalents, and restricted cash, beginning of period | 285,621 | 262,646 | 144,894 | NaN |
| Cash, cash equivalents, and restricted cash end of period | 311,212 | 285,621 | 262,646 | NaN |
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)